Optimal Use of Taxanes in Metastatic Breast Cancer (MBC)

This is a clinical practice guideline for adults over the age of 18 years with metastatic breast cancer who are anthracycline naïve or pre-treated/resistant. The guideline examines the use of taxane treatment for women depending on whether they have previously been treated with anthracycline, and whether or not the tumour shows HER2 overexpression. The guideline also reviews the use of taxanes to treat women who are anthracycline naïve or pretreated/resistant and paclitaxel or docetaxel intolerant. Outcomes of interest include risk of disease progression, toxicity rates, adverse effects of treatment, response rates, mortality, and quality of life.